» Articles » PMID: 24033561

Treated and Untreated Women with Idiopathic Precocious Puberty: Long-term Follow-up and Reproductive Outcome Between the Third and Fifth Decades

Overview
Specialty Endocrinology
Date 2013 Sep 17
PMID 24033561
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Central precocious puberty (CPP), treated or untreated, may have implications in adulthood.

Objective: To assess the reproductive outcome and social adjustment of former CPP women between the 3rd and 5th decades of life.

Design: Cross-sectional study of an historical cohort.

Methods: Demographic data and gynaecological history of 214 CPP women aged 25-56 years [135 GnRH analogue (GnRHa)-treated, 18 cyproterone acetate (CyA)-treated, 61 untreated] and of 446 controls with normal puberty, matched for age and year of birth, were recorded in a structured interview.

Results: Marital status, education and number of children were similar in CPP women and controls. Clinical hyperandrogenism (acne/hirsutism with oligomenorrhoea) was more frequently reported in CPP women than in controls: GnRHa-treated 29·6% vs 17·4% (P = 0·006), CyA-treated 50% vs 20·4% (P = 0·04), untreated 34·4% vs 17·2% (P = 0·003), with no significant difference between CPP groups. Spontaneous pregnancy was similarly achieved by treated CPP and controls: GnRHa-treated 90·4% vs 93·4%, CyA-treated 86·7% vs 90·2%. Assisted fertilization rate was higher in untreated CPP than treated CPP groups (P = 0·006) and controls (P = 0·03). Untreated CPP was the only parameter associated with clinical hyperandrogenism (OR=2·04, 95% CI, 1·0-4·16, P = 0·07) and fertility problems (OR=3·40, 95% CI, 1·15-10·0, P = 0·047). Course of pregnancy was uneventful in 90·2% of CPP women and 90·9% of controls.

Conclusions: The increased rate of clinical hyperandrogenism among CPP women implies that the underlying neuroendocrine dysfunction persists into adult life. Pubertal suppression treatment may have a protective effect as fertility problems were more prevalent only among untreated CPP women. Educational achievements and marital status were unaffected by CPP.

Citing Articles

Shared Pathophysiological Mechanisms and Genetic Factors in Early Menarche and Polycystic Ovary Syndrome.

Tinano F, Machado I, Latronico A, Gomes L J Neurosci. 2025; 45(11).

PMID: 40074331 PMC: 11905354. DOI: 10.1523/JNEUROSCI.1681-24.2024.


Long-term health consequences of central precocious/early puberty (CPP) and treatment with Gn-RH analogue: a short update.

Soliman A, Alaaraj N, De Sanctis V, Hamed N, Alyafei F, Ahmed S Acta Biomed. 2023; 94(6):e2023222.

PMID: 38054666 PMC: 10734238. DOI: 10.23750/abm.v94i6.15316.


2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents.

Kim S, Kim J, Hong Y, Chung I, Lee E, Kang E Ann Pediatr Endocrinol Metab. 2023; 28(3):168-177.

PMID: 37798893 PMC: 10556443. DOI: 10.6065/apem.2346168.084.


Effect of gonadotropin-releasing hormone analogue treatment in improving final adult height of children with central precocious puberty or early and fast puberty: a Meta analysis.

Chu Z, Jiang H, Wu Q Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(11):1161-1168.

PMID: 34753549 PMC: 8580025. DOI: 10.7499/j.issn.1008-8830.2108078.


Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study.

Karavani G, Chill H, Schachter-Safrai N, Lomnitz G, Gillis D, Bauman D Clin Diabetes Endocrinol. 2021; 7(1):14.

PMID: 34521474 PMC: 8442439. DOI: 10.1186/s40842-021-00129-4.